Email: cspc@cspc.cn
News
News Center
May. 02
2025
JMT202 (RECOMBINANT FULLY HUMAN ANTI-βKLOTHO MONOCLONAL ANTIBODY DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Apr. 30
VOLUNTARY ANNOUNCEMENT - PIVOTAL PHASE II/III CLINICAL STUDY OF KN026 MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS) AT INTERIM ANALYSIS
Apr. 25
VOLUNTARY ANNOUNCEMENT - SYH2068 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL
Apr. 22
VOLUNTARY ANNOUNCEMENT - JMT203 (ANTI-GFRAL MONOCLONAL ANTIBODY) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
VOLUNTARY ANNOUNCEMENT - PRUSOGLIPTIN AND METFORMIN EXTENDED-RELEASE TABLETS OBTAINS CLINICAL TRIAL APPROVAL
Apr. 15
VOLUNTARY ANNOUNCEMENT - OSELTAMIVIR PHOSPHATE FOR SUSPENSION OBTAINS DRUG REGISTRATION APPROVAL
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
